These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

559 related items for PubMed ID: 28805135

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
    Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV.
    Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.
    Ann Oncol; 2017 Jul 01; 28(7):1631-1639. PubMed ID: 28475671
    [Abstract] [Full Text] [Related]

  • 7. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.
    Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA.
    Lancet Oncol; 2020 Sep 01; 21(9):1234-1243. PubMed ID: 32818466
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combination of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600E-Mutated Thyroid Cancer.
    Jeon Y, Park S, Lee SH, Kim TH, Kim SW, Ahn MJ, Jung HA, Chung JH.
    Cancer Res Treat; 2024 Oct 01; 56(4):1270-1276. PubMed ID: 38453274
    [Abstract] [Full Text] [Related]

  • 10. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
    Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A.
    Nat Med; 2020 Oct 01; 26(10):1564-1568. PubMed ID: 33020646
    [Abstract] [Full Text] [Related]

  • 11. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
    Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B.
    J Clin Oncol; 2018 Jan 01; 36(1):7-13. PubMed ID: 29072975
    [Abstract] [Full Text] [Related]

  • 12. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
    Khunger A, Khunger M, Velcheti V.
    Ther Adv Respir Dis; 2018 Jan 01; 12():1753466618767611. PubMed ID: 29595366
    [Abstract] [Full Text] [Related]

  • 13. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
    Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.
    N Engl J Med; 2019 Aug 15; 381(7):626-636. PubMed ID: 31166680
    [Abstract] [Full Text] [Related]

  • 14. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM.
    N Engl J Med; 2017 Nov 09; 377(19):1813-1823. PubMed ID: 28891408
    [Abstract] [Full Text] [Related]

  • 15. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.
    N Engl J Med; 2015 Jan 01; 372(1):30-9. PubMed ID: 25399551
    [Abstract] [Full Text] [Related]

  • 16. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L, Zhang X, Shin SJ, Fan Y, Lin CC, Kim TM, Dechaphunkul A, Maneechavakajorn J, Wong CS, Ilankumaran P, Lee DY, Gasal E, Li H, Guo J.
    Eur J Cancer; 2020 Aug 01; 135():31-38. PubMed ID: 32534242
    [Abstract] [Full Text] [Related]

  • 17. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.
    Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski CC, Cabanillas ME, Boran A, Ilankumaran P, Burgess P, Romero Salas T, Keam B.
    Ann Oncol; 2022 Apr 01; 33(4):406-415. PubMed ID: 35026411
    [Abstract] [Full Text] [Related]

  • 18. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K.
    N Engl J Med; 2014 Nov 13; 371(20):1877-88. PubMed ID: 25265492
    [Abstract] [Full Text] [Related]

  • 19. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
    Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV.
    Lancet Oncol; 2017 Jul 13; 18(7):863-873. PubMed ID: 28592387
    [Abstract] [Full Text] [Related]

  • 20. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAFV600E-mutated poorly differentiated thyroid cancer: A case report and review of the literature.
    Zeng Q, Deng Y, Zhang L, Wang W.
    Int J Clin Pharmacol Ther; 2022 May 13; 60(5):225-231. PubMed ID: 35072623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.